CJ PARTNERS, Inc. is a Tokyo-based life science consultancy and CRO specializing in regenerative medicine but with broad experience across other technologies including biologics and medical devices. We offer start-to-finish services from market analysis to IND/IMPD/CTN submission, to clinical operations support. Additionally, we provide investment support with Japanese investors.

Strategic Advisory
CJP understands that detailed information regarding the Japanese market is often hidden behind linguistic barriers. We collect primary and secondary data to paint an analytical landscape of the Japanese market to drive your clinical and commercial decisions in Japan. Additionally, we can spearhead your discussions with strategic partners from licensing to manufacturing and everything in between.

Regulatory Advisory
CJP has conducted more than 30 consultations with the PMDA for regenerative medicine products across multiple indication areas, administration methods, and mechanisms of action. We also processed the first Accreditation Certificate of a Foreign Cell Processor for a biotech outside of Asia.

Clinical Operations
CJP understands and has extensive experience with the unique challenges facing the delivery and administration of cell and gene therapies, whether autologous or allogeneic. CJP has designed multiple trials for regenerative medicine products, whether administered alone, in combination with an approved drug, or in combination with an unapproved medical device.

Investor/VC Advisory
Relatively little known outside of Japan, there are opportunities for investment from Japanese VCs, corporate venture funds. and privately wealthy individuals with interests in the biotech and life science space. CJP has a strong network of investors who have come to depend on CJP to introduce unique opportunities.

CJ PARTNERS Inc.

Org chart

Teams

Offices